Evidence map›Paper›PMID 36920028›Full record

ArticleeLife2023

Inactivation of

Yuanyuan Li, Wenyan Xu, Svetlana Makova, Martina Brueckner, Zhaoxia Sun

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. CaAntibodies (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Dimerization activates the Inversin complex inMolecular biology of the cell · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yuanyuan Li *Department of Genetics, Yale University School of Medicine, New Haven, United States.
Wenyan Xu *Department of Genetics, Yale University School of Medicine, New Haven, United States.
Svetlana MakovaDepartment of Pediatrics, Yale University School of Medicine, New Haven, United States.
Martina BruecknerDepartment of Pediatrics, Yale University School of Medicine, New Haven, United States.
Zhaoxia SunDepartment of Genetics, Yale University School of Medicine, New Haven, United States.ORCID 0000-0002-2307-7719
Yale University · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI SOMLO, STEFAN · 2008 to 2022
$16.8M
Cilia in Heart Development and DiseaseR35HL145249 · NHLBI · YALE UNIVERSITY · PI BRUECKNER, MARTINA · 2019 to 2025
$5.2M
Role of Cilia in Renal FibrosisR01DK113135 · NIDDK · YALE UNIVERSITY · PI ZHAOXIA SUN · 2017 to 2026
$4.3M
Genetic Analysis of Organ Patterning Defects in CiliopathiesR01HD093608 · NICHD · YALE UNIVERSITY · PI SUN, ZHAOXIA · 2018 to 2022
$1.9M
NHLBI NIH HHS R35 HL145249NICHD NIH HHS R01 HD093608NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK113135
6 · The paper itself

Abstract

Nephronophthisis (NPHP) is a ciliopathy characterized by renal fibrosis and cyst formation, and accounts for a significant portion of end stage renal disease in children and young adults. Currently, no targeted therapy is available for this disease.

Indexed as

CystsKidney Diseases, CysticPolycystic Kidney DiseasesAnimalsCadherinsCiliaEpithelial CellsFibrosisMiceMice, KnockoutPhenotypeTranscription FactorsCadherinsCdh16 protein, mouseTranscription Factorscell biologyciliadevelopmental biologyfibrosishistone deacetylase inhibitor HDACImousenephronophthisis NPHPnphp2/Invpolycystic kidney disease PKD

Identifiers

PMID36920028
PMCPMC10154023
OpenAlexW4324311580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.